Zhejiang Medicine Co., Ltd. Class ASSE: 600216

Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights

· Issued by Zhejiang Medicine Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis